Open Access

Suppression of hepatic dysfunction in tenascin‑X‑deficient mice fed a high‑fat diet

  • Authors:
    • Shinsaku Yamaguchi
    • Kohei Kawakami
    • Kazumi Satoh
    • Naoki Fukunaga
    • Kazuhito Akama
    • Ken‑Ichi Matsumoto
  • View Affiliations

  • Published online on: July 21, 2017     https://doi.org/10.3892/mmr.2017.7052
  • Pages: 4061-4067
  • Copyright: © Yamaguchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Extracellular matrix glycoprotein tenascin‑X (TNX) is the largest member of the tenascin family. In the present study, the contribution of TNX to liver dysfunction was investigated by administration of high‑fat and high‑cholesterol diet with high levels of phosphorus and calcium (HFCD) to wild‑type (WT) and TNX‑knockout (KO) mice. After 16 weeks of HFCD administration, the ratio of liver weight to body weight was approximately 22% higher in the HFCD‑fed WT mice compared with the HFCD‑fed TNX‑KO mice, indicating hepatomegaly in HFCD‑fed WT mice. Histological analyses with hematoxylin and eosin staining at 21 weeks revealed that hepatocyte hypertrophy in HFCD‑fed TNX‑KO mice was suppressed to 85% of that in HFCD‑fed WT mice. By contrast, there was a 1.2‑fold increase in lipid deposition in hepatocytes from HFCD‑fed TNX‑KO mice compared with HFCD‑fed WT mice at 18 weeks, as demonstrated by Oil Red O staining. In addition, TNX‑KO mice at 21 weeks and 27 weeks post‑HFCD administration exhibited significant suppression of inflammatory cell infiltrate to 51 and 24% of that in WT mice, respectively. Immunofluorescence analysis for type I collagen and Elastica van Gieson staining demonstrated a clear hepatic fibrosis progression in HFCD‑fed WT mice at 27 weeks, whereas hepatic fibrosis was undetected in HFCD‑fed TNX‑KO mice. The present findings indicated that TNX deficiency suppressed hepatic dysfunction induced by HFCD administration.

Related Articles

Journal Cover

October-2017
Volume 16 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yamaguchi S, Kawakami K, Satoh K, Fukunaga N, Akama K and Matsumoto KI: Suppression of hepatic dysfunction in tenascin‑X‑deficient mice fed a high‑fat diet. Mol Med Rep 16: 4061-4067, 2017
APA
Yamaguchi, S., Kawakami, K., Satoh, K., Fukunaga, N., Akama, K., & Matsumoto, K. (2017). Suppression of hepatic dysfunction in tenascin‑X‑deficient mice fed a high‑fat diet. Molecular Medicine Reports, 16, 4061-4067. https://doi.org/10.3892/mmr.2017.7052
MLA
Yamaguchi, S., Kawakami, K., Satoh, K., Fukunaga, N., Akama, K., Matsumoto, K."Suppression of hepatic dysfunction in tenascin‑X‑deficient mice fed a high‑fat diet". Molecular Medicine Reports 16.4 (2017): 4061-4067.
Chicago
Yamaguchi, S., Kawakami, K., Satoh, K., Fukunaga, N., Akama, K., Matsumoto, K."Suppression of hepatic dysfunction in tenascin‑X‑deficient mice fed a high‑fat diet". Molecular Medicine Reports 16, no. 4 (2017): 4061-4067. https://doi.org/10.3892/mmr.2017.7052